Julie Anna Wolfson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julie Anna Wolfson has a total of 281 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer M. Levine
Center for Cancer and Blood Disorders Children's National Hospital Washington, DC USA
9 shared publications Smita Bhatia
Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham Alabama USA
9 shared publications- Smita Bhatia
University of Alabama at Birmingham, Birmingham, AL
8 shared publications Carla Schwalm
Pediatric Hematology‐Oncology Department of Pediatrics Bronson Methodist Hospital Kalamazoo Michigan USA
6 shared publications- David S. Dickens
The University of Iowa
6 shared publications Can-Lan Sun
Department of Population Sciences, City of Hope National Medical Center, Duarte, California; and
5 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3664-3675
Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia
The best frontline treatment for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs) is unclear. To support a clinical practice guideline, we systematically reviewed and meta-analyzed evidence on (1) asparaginase-based (pediatric) vs non–asparaginase-based (adult) regimens and (2) allogeneic hematopoietic stem cell transplantation (HSCT) vs no HSCT for AYAs (aged 15-39 years) with ALL in first complete remission. Data sources were PubMed, CINAHL, and PsycINFO from inception to 29 November 2023. Eligible studies compared regimens or the use of HSCT and reported survival, remission, toxicity, or quality of life in AYAs. We included 19 studies (14 comparative, 5 single-group; N = 3607) comparing regimens and 7 studies (N = 7492) comparing HSCT and no HSCT. Studies were mostly of poor quality, with sparse randomized controlled trials (RCTs), yielding low-certainty findings. Pediatric regimens were associated with higher 5-year overall survival (OS; relative risk [RR], 1.40; 95% confidence interval [CI], 1.18-1.65), event-free survival (RR, 1.80; 95% CI, 1.13-2.85), disease-free survival (DFS; RR, 1.55; 95% CI, 1.32-1.82), and lower treatment-related mortality (TRM; RR, 0.29; 95% CI, 0.09-0.90). HSCT was associated with lower 5-year OS (RR, 0.72; 95% CI, 0.61-0.84) and DFS (RR, 0.78; 95% CI, 0.68-0.90) and higher nonrelapse mortality (RR, 2.70; 95% CI, 1.18-6.18) and TRM (hazard ratio, 6.88; 95% CI, 3.02-15.70). Relapse risk varied by time point. In AYAs with Philadelphia chromosome–negative ALL, pediatric regimens may improve survival; toxicity-related evidence remains limited. HSCT may lead to inferior OS and DFS. With a dearth of RCTs, low-certainty evidence highlights the need for high-quality studies and subanalyses of AYAs.
- 15 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3664-3675
Open AccessPediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia
The best frontline treatment for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs) is unclear. To support a clinical practice guideline, we systematically reviewed and meta-analyzed evidence on (1) asparaginase-based (pediatric) vs non–asparaginase-based (adult) regimens and (2) allogeneic hematopoietic stem cell transplantation (HSCT) vs no HSCT for AYAs (aged 15-39 years) with ALL in first complete remission. Data sources were PubMed, CINAHL, and PsycINFO from inception to 29 November 2023. Eligible studies compared regimens or the use of HSCT and reported survival, remission, toxicity, or quality of life in AYAs. We included 19 studies (14 comparative, 5 single-group; N = 3607) comparing regimens and 7 studies (N = 7492) comparing HSCT and no HSCT. Studies were mostly of poor quality, with sparse randomized controlled trials (RCTs), yielding low-certainty findings. Pediatric regimens were associated with higher 5-year overall survival (OS; relative risk [RR], 1.40; 95% confidence interval [CI], 1.18-1.65), event-free survival (RR, 1.80; 95% CI, 1.13-2.85), disease-free survival (DFS; RR, 1.55; 95% CI, 1.32-1.82), and lower treatment-related mortality (TRM; RR, 0.29; 95% CI, 0.09-0.90). HSCT was associated with lower 5-year OS (RR, 0.72; 95% CI, 0.61-0.84) and DFS (RR, 0.78; 95% CI, 0.68-0.90) and higher nonrelapse mortality (RR, 2.70; 95% CI, 1.18-6.18) and TRM (hazard ratio, 6.88; 95% CI, 3.02-15.70). Relapse risk varied by time point. In AYAs with Philadelphia chromosome–negative ALL, pediatric regimens may improve survival; toxicity-related evidence remains limited. HSCT may lead to inferior OS and DFS. With a dearth of RCTs, low-certainty evidence highlights the need for high-quality studies and subanalyses of AYAs.
- Open Access
- 12 January 2026
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 13 (1) , 73-84
Survival Outcomes with Guideline-Concordant Pediatric-Inspired Regimens in Adolescent/Young Adult Acute Lymphoblastic Leukemia: Retrospective Real-World Analysis
Background Pediatric-inspired regimens (PIR) yield excellent outcomes for acute lymphoblastic leukemia (ALL). Despite national guidelines recommending PIR for adolescents and young adults (AYAs; aged 15–39 years), the use of guideline-concordant PIR in AYAs is inconsistent across treatment settings. Methods This retrospective observational study compared overall survival (OS) and stem cell transplant (SCT) use among AYAs treated with PIR versus non-PIR. Using a deidentified, geographically representative USA health claims database, we analyzed a cohort of AYAs with newly diagnosed ALL between 1 July 2007 and 30 September 2020. Results Among 599 patients who met the inclusion criteria, 187 (31%) received PIR, 303 (51%) received non-PIR, and for 109 (18%), treatment was undetermined. PIR and non-PIR groups were propensity score matched (n = 187 each). Using Kaplan–Meier methodology, OS was significantly higher for those treated with PIR versus non-PIR (log-rank P = 0.0001; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.18–0.55). For PIR and non-PIR, 1-, 3-, and 5-year survival estimates (95% CI) were 98.1% (95.3–99.3%) versus 88.3% (83.5–91.7%); 88.5% (82.6–92.5%) versus 69.1% (62.1–75.1%); and 87.3% (81.0–91.6%) versus 63.3% (55.2–70.3%). Sensitivity and subgroup analyses were consistent with primary results. By Kaplan–Meier methodology, SCT use was significantly lower among AYAs treated with PIR than non-PIR (log-rank P = 0.0004; HR, 0.46; 95% CI 0.30–0.71); use by 2 years was 16.5% (12.2–22.2%) and 33.4% (27.6–40.0%), respectively. Conclusions These results support the use of guideline-concordant PIR for AYA ALL.
- 12 January 2026
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 13 (1) , 73-84
Open AccessSurvival Outcomes with Guideline-Concordant Pediatric-Inspired Regimens in Adolescent/Young Adult Acute Lymphoblastic Leukemia: Retrospective Real-World Analysis
Background Pediatric-inspired regimens (PIR) yield excellent outcomes for acute lymphoblastic leukemia (ALL). Despite national guidelines recommending PIR for adolescents and young adults (AYAs; aged 15–39 years), the use of guideline-concordant PIR in AYAs is inconsistent across treatment settings. Methods This retrospective observational study compared overall survival (OS) and stem cell transplant (SCT) use among AYAs treated with PIR versus non-PIR. Using a deidentified, geographically representative USA health claims database, we analyzed a cohort of AYAs with newly diagnosed ALL between 1 July 2007 and 30 September 2020. Results Among 599 patients who met the inclusion criteria, 187 (31%) received PIR, 303 (51%) received non-PIR, and for 109 (18%), treatment was undetermined. PIR and non-PIR groups were propensity score matched (n = 187 each). Using Kaplan–Meier methodology, OS was significantly higher for those treated with PIR versus non-PIR (log-rank P = 0.0001; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.18–0.55). For PIR and non-PIR, 1-, 3-, and 5-year survival estimates (95% CI) were 98.1% (95.3–99.3%) versus 88.3% (83.5–91.7%); 88.5% (82.6–92.5%) versus 69.1% (62.1–75.1%); and 87.3% (81.0–91.6%) versus 63.3% (55.2–70.3%). Sensitivity and subgroup analyses were consistent with primary results. By Kaplan–Meier methodology, SCT use was significantly lower among AYAs treated with PIR than non-PIR (log-rank P = 0.0004; HR, 0.46; 95% CI 0.30–0.71); use by 2 years was 16.5% (12.2–22.2%) and 33.4% (27.6–40.0%), respectively. Conclusions These results support the use of guideline-concordant PIR for AYA ALL.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (1) , 112-121
Fertility Preservation Services for Adolescents and Young Adults: 2022 National Cancer Institute Community Oncology Research Program Landscape Assessment
PURPOSE: Given the impact of cancer treatment on fertility among adolescents and young adults (AYAs: 15-39 years), it is important to ensure AYAs access to fertility preservation (FP). However, the availability of FP services for AYAs treated in community settings is unknown. We examined FP access at National Cancer Institute Community Oncology Research Program (NCORP) practice groups. METHODS: The 2022 NCORP Landscape Assessment survey captured available resources and cancer care services including FP services at practice groups. We described FP services as accessible (on-site or off-site) versus not accessible by AYA-treating status (as previously defined). Univariable and multivariable analyses were used to evaluate associations between FP services and practice characteristics (NCORP classification [minority/underserved or community] and proportion of Medicaid or uninsured above/below the national average). RESULTS: Among 271 practice groups responding to the survey, 100 were categorized as AYA-treating, of which 32% had neither male nor female FP services available. Sperm banking was available at 59 AYA-treating practices, among which 43 (73%) referred for sperm banking off-site. Although approximately half of AYA-treating practices reported accessible female FP services (embryo = 54%, oocyte = 55%, ovarian tissue = 40%), most of them referred patients off-site (embryo = 72%, oocyte = 80%, ovarian tissue = 83%). The odds of access to male FP were lower at minority/underserved practices (odds ratio, 0.34 [95% CI, 0.13 to 0.88]; P = .026; ref = community); however, this same relationship was not seen for females. CONCLUSION: Despite guidelines surrounding FP discussions before cancer therapy, and strong consensus regarding the importance of FP access, many AYA-treating practices in community settings lack access to FP services. Understanding how to leverage available services and broadly expand access is urgently needed to facilitate guideline-concordant, high-quality cancer care for AYAs.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (1) , 112-121
Fertility Preservation Services for Adolescents and Young Adults: 2022 National Cancer Institute Community Oncology Research Program Landscape Assessment
PURPOSE: Given the impact of cancer treatment on fertility among adolescents and young adults (AYAs: 15-39 years), it is important to ensure AYAs access to fertility preservation (FP). However, the availability of FP services for AYAs treated in community settings is unknown. We examined FP access at National Cancer Institute Community Oncology Research Program (NCORP) practice groups. METHODS: The 2022 NCORP Landscape Assessment survey captured available resources and cancer care services including FP services at practice groups. We described FP services as accessible (on-site or off-site) versus not accessible by AYA-treating status (as previously defined). Univariable and multivariable analyses were used to evaluate associations between FP services and practice characteristics (NCORP classification [minority/underserved or community] and proportion of Medicaid or uninsured above/below the national average). RESULTS: Among 271 practice groups responding to the survey, 100 were categorized as AYA-treating, of which 32% had neither male nor female FP services available. Sperm banking was available at 59 AYA-treating practices, among which 43 (73%) referred for sperm banking off-site. Although approximately half of AYA-treating practices reported accessible female FP services (embryo = 54%, oocyte = 55%, ovarian tissue = 40%), most of them referred patients off-site (embryo = 72%, oocyte = 80%, ovarian tissue = 83%). The odds of access to male FP were lower at minority/underserved practices (odds ratio, 0.34 [95% CI, 0.13 to 0.88]; P = .026; ref = community); however, this same relationship was not seen for females. CONCLUSION: Despite guidelines surrounding FP discussions before cancer therapy, and strong consensus regarding the importance of FP access, many AYA-treating practices in community settings lack access to FP services. Understanding how to leverage available services and broadly expand access is urgently needed to facilitate guideline-concordant, high-quality cancer care for AYAs.
- 4 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32126
COVID‐19 Reinfection in Children With Cancer: Clinical Course and Risk Factors
While children with cancer are at risk of severe COVID‐19, little is known about reinfection. Among infections ( n = 2075) in children (≤ 21 years old, median age = 10 years old) receiving cancer‐directed therapy and reported to the Pediatric Oncology COVID‐19 case report, reinfection represented 6%. Children with subsequent infections did not have lower odds of hospitalization, intensive care unit admission, or changes to cancer‐directed therapy. Odds of reinfection were higher among children with hematologic malignancies but did not vary with sociodemographics, disease status, comorbidities, or vaccination status. The disease course for reinfected children was not less severe than the first infection, emphasizing the importance of preventing reinfection.
- 4 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32126
COVID‐19 Reinfection in Children With Cancer: Clinical Course and Risk Factors
While children with cancer are at risk of severe COVID‐19, little is known about reinfection. Among infections ( n = 2075) in children (≤ 21 years old, median age = 10 years old) receiving cancer‐directed therapy and reported to the Pediatric Oncology COVID‐19 case report, reinfection represented 6%. Children with subsequent infections did not have lower odds of hospitalization, intensive care unit admission, or changes to cancer‐directed therapy. Odds of reinfection were higher among children with hematologic malignancies but did not vary with sociodemographics, disease status, comorbidities, or vaccination status. The disease course for reinfected children was not less severe than the first infection, emphasizing the importance of preventing reinfection.
- Open Access
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
T cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges
Infiltration of T cell acute lymphoblastic leukemia (T-ALL) into the meninges worsens prognosis, underscoring the need to understand mechanisms driving meningeal involvement. Here, we show that T-ALL cells expressing CXCR3 exploit normal T cell function to infiltrate the inflamed meninges. CXCR3 deletion hampered disease progression and extramedullary dissemination by reducing leukemic cell proliferation and migration. Conversely, forced expression of CXCR3 facilitated T-ALL trafficking to the meninges. We identified the ubiquitin-specific protease 7 as a key regulator of CXCR3 protein stability in T-ALL. Furthermore, we discovered elevated levels of CXCL10, a CXCR3 ligand, in the cerebrospinal fluid from patients with T-ALL and leukemia-bearing mice. Our studies demonstrate that meningeal stromal cells, specifically pericytes and fibroblasts, induce CXCL10 expression in response to leukemia and that loss of CXCL10 attenuated T-ALL influx into the meninges. Moreover, we report that leukemia-derived proinflammatory cytokines, TNF-α, IL-27, and IFN-γ, induced CXCL10 in the meningeal stroma. Pharmacological inhibition or deletion of CXCR3 or CXCL10 reduced T-ALL cell migration and adhesion to meningeal stromal cells. Finally, we reveal that CXCR3 and CXCL10 upregulated VLA-4/VCAM-1 signaling, promoting cell-cell adhesion and thus T-ALL retention in the meninges. Our findings highlight the pivotal role of CXCR3-CXCL10 signaling in T-ALL progression and meningeal colonization.
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Open AccessT cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges
Infiltration of T cell acute lymphoblastic leukemia (T-ALL) into the meninges worsens prognosis, underscoring the need to understand mechanisms driving meningeal involvement. Here, we show that T-ALL cells expressing CXCR3 exploit normal T cell function to infiltrate the inflamed meninges. CXCR3 deletion hampered disease progression and extramedullary dissemination by reducing leukemic cell proliferation and migration. Conversely, forced expression of CXCR3 facilitated T-ALL trafficking to the meninges. We identified the ubiquitin-specific protease 7 as a key regulator of CXCR3 protein stability in T-ALL. Furthermore, we discovered elevated levels of CXCL10, a CXCR3 ligand, in the cerebrospinal fluid from patients with T-ALL and leukemia-bearing mice. Our studies demonstrate that meningeal stromal cells, specifically pericytes and fibroblasts, induce CXCL10 expression in response to leukemia and that loss of CXCL10 attenuated T-ALL influx into the meninges. Moreover, we report that leukemia-derived proinflammatory cytokines, TNF-α, IL-27, and IFN-γ, induced CXCL10 in the meningeal stroma. Pharmacological inhibition or deletion of CXCR3 or CXCL10 reduced T-ALL cell migration and adhesion to meningeal stromal cells. Finally, we reveal that CXCR3 and CXCL10 upregulated VLA-4/VCAM-1 signaling, promoting cell-cell adhesion and thus T-ALL retention in the meninges. Our findings highlight the pivotal role of CXCR3-CXCL10 signaling in T-ALL progression and meningeal colonization.
- Open Access
- 16 April 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia
Background: Individuals diagnosed with acute lymphoblastic leukemia (ALL) between adolescents and young adults aged 15-39 years face poor survival and unique challenges. We evaluated facility-level factors and guideline-concordant care among adolescents and young adults with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices. Methods: We assembled a retrospective cohort of adolescents and young adults aged 15-39 years with ALL treated at participating NCORPs between 2012 and 2016. NCORPs abstracted patient data and completed facility-level questionnaires for each clinical facility (study-defined criteria). The central review committee adjudicated whether treatment was concordant with adolescent and young adult–specific National Comprehensive Cancer Network ALL guidelines (ie, pediatric-inspired therapy or clinical trial). Guideline-concordant care was described by age, facility model (adult/internal medicine, pediatric, mixed [pediatric services within a general hospital]), and average annual adolescents and young adult ALL volume. Generalized linear mixed effects models estimated the odds of guideline-concordant care. Results: Adolescents and young adults receiving guideline-concordant care were younger (n = 196; median = 19.5 years) than those who did not (n = 31; median = 32.1 years). Guideline-concordant care was observed in many adolescents and young adults aged 22-39 years (68.8%), and nearly universal in those aged 15-21 years. In multivariable analyses, adolescents and young adults at adult/internal medicine clinical facilities had lower odds of guideline-concordant care (odds ratio = 0.02, 95% confidence interval = 0.0 to 0.18); there was no statistically significant association between annual adolescent and young ALL volume and receiving guideline-concordant care. Guideline-concordant care was observed more often in adult/internal medicine and/or mixed clinical facilities with communication between adult or pediatric counterparts, adolescents and young adult ALL clinical pathways, and/or adolescent and young adult–specific meetings. Conclusion: Guideline-concordant care among adolescents and young adults with ALL (specifically pediatric-inspired therapy) at NCORPs is associated with facility model (adult/internal medicine) but not adolescent and young adult ALL volume. Strategies to improve guideline-concordant care could include facilitating communication and clinical pathways at adult/internal medicine clinical facilities treating adolescent and young adult ALL.
- 16 April 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Open AccessGuideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia
Background: Individuals diagnosed with acute lymphoblastic leukemia (ALL) between adolescents and young adults aged 15-39 years face poor survival and unique challenges. We evaluated facility-level factors and guideline-concordant care among adolescents and young adults with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices. Methods: We assembled a retrospective cohort of adolescents and young adults aged 15-39 years with ALL treated at participating NCORPs between 2012 and 2016. NCORPs abstracted patient data and completed facility-level questionnaires for each clinical facility (study-defined criteria). The central review committee adjudicated whether treatment was concordant with adolescent and young adult–specific National Comprehensive Cancer Network ALL guidelines (ie, pediatric-inspired therapy or clinical trial). Guideline-concordant care was described by age, facility model (adult/internal medicine, pediatric, mixed [pediatric services within a general hospital]), and average annual adolescents and young adult ALL volume. Generalized linear mixed effects models estimated the odds of guideline-concordant care. Results: Adolescents and young adults receiving guideline-concordant care were younger (n = 196; median = 19.5 years) than those who did not (n = 31; median = 32.1 years). Guideline-concordant care was observed in many adolescents and young adults aged 22-39 years (68.8%), and nearly universal in those aged 15-21 years. In multivariable analyses, adolescents and young adults at adult/internal medicine clinical facilities had lower odds of guideline-concordant care (odds ratio = 0.02, 95% confidence interval = 0.0 to 0.18); there was no statistically significant association between annual adolescent and young ALL volume and receiving guideline-concordant care. Guideline-concordant care was observed more often in adult/internal medicine and/or mixed clinical facilities with communication between adult or pediatric counterparts, adolescents and young adult ALL clinical pathways, and/or adolescent and young adult–specific meetings. Conclusion: Guideline-concordant care among adolescents and young adults with ALL (specifically pediatric-inspired therapy) at NCORPs is associated with facility model (adult/internal medicine) but not adolescent and young adult ALL volume. Strategies to improve guideline-concordant care could include facilitating communication and clinical pathways at adult/internal medicine clinical facilities treating adolescent and young adult ALL.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (12) , 1655-1662
COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk
PURPOSE: Unlike most childhood cancers, therapy for ALL includes a prolonged maintenance phase during which children typically resume regular activities. Physicians need data regarding the persistent impact of COVID-19 in this population to help guide families after the pandemic. METHODS: The Pediatric Oncology COVID-19 Case Report (POCC) collects deidentified data (sociodemographics, clinical data [cancer, COVID-19 course]) on children, adolescents, and young adults with cancer and COVID-19 from 104 US pediatric oncology institutions. The analysis presented here compares children (≤21 years) with ALL in maintenance (ALL-MTN) with all other children with cancer and COVID-19. Multivariable analyses adjust for age, race/ethnicity, insurance, absolute neutrophil count at the time of infection, vaccination, and comorbidities. RESULTS: Compared with other children reported to POCC (n = 1,190), those in ALL-MTN (n = 481) were less often hospitalized (23% v 29%, P = .01) or admitted to the intensive care unit (ICU: 3% v 5%, P = .01); these findings persisted in multivariable analysis (hospitalization: odds ratio [OR], 0.7 [95% CI, 0.6 to 0.9]; ICU: OR, 0.5 [95% CI, 0.2 to 0.8]). However, cancer-directed therapy was changed more often for children in ALL-MTN (50% v 33%, P ≤ .01; OR, 2.0 [95% CI, 1.6 to 2.5[). Vaccination was an independent prognostic factor in our multivariable model, decreasing odds of hospitalization (OR, 0.7 [95% CI, 0.5 to 0.9]). CONCLUSION: Children in ALL-MTN required fewer hospitalizations and ICU admissions but more therapy modifications than other children with cancer. Vaccination against COVID-19 reduced the odds of hospitalization.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (12) , 1655-1662
COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk
PURPOSE: Unlike most childhood cancers, therapy for ALL includes a prolonged maintenance phase during which children typically resume regular activities. Physicians need data regarding the persistent impact of COVID-19 in this population to help guide families after the pandemic. METHODS: The Pediatric Oncology COVID-19 Case Report (POCC) collects deidentified data (sociodemographics, clinical data [cancer, COVID-19 course]) on children, adolescents, and young adults with cancer and COVID-19 from 104 US pediatric oncology institutions. The analysis presented here compares children (≤21 years) with ALL in maintenance (ALL-MTN) with all other children with cancer and COVID-19. Multivariable analyses adjust for age, race/ethnicity, insurance, absolute neutrophil count at the time of infection, vaccination, and comorbidities. RESULTS: Compared with other children reported to POCC (n = 1,190), those in ALL-MTN (n = 481) were less often hospitalized (23% v 29%, P = .01) or admitted to the intensive care unit (ICU: 3% v 5%, P = .01); these findings persisted in multivariable analysis (hospitalization: odds ratio [OR], 0.7 [95% CI, 0.6 to 0.9]; ICU: OR, 0.5 [95% CI, 0.2 to 0.8]). However, cancer-directed therapy was changed more often for children in ALL-MTN (50% v 33%, P ≤ .01; OR, 2.0 [95% CI, 1.6 to 2.5[). Vaccination was an independent prognostic factor in our multivariable model, decreasing odds of hospitalization (OR, 0.7 [95% CI, 0.5 to 0.9]). CONCLUSION: Children in ALL-MTN required fewer hospitalizations and ICU admissions but more therapy modifications than other children with cancer. Vaccination against COVID-19 reduced the odds of hospitalization.
- Open Access
- 28 May 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (8) , e31082
COVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies
Introduction: Children, adolescents, and young adults (CAYAs) with Down syndrome (DS) and hematologic malignancies are particularly vulnerable to infections and related complications. There are limited data regarding COVID‐19 infections in this group. We aimed to understand the clinical course of COVID‐19 in this population. Methods: This observational study leverages the de‐identified clinical and sociodemographic data captured by the Pediatric Oncology COVID‐19 Case Report Registry (POCC) regarding CAYAs with cancer and COVID‐19. We evaluated CAYAs (≤21 years at COVID‐19 infection) with hematologic malignancies and COVID‐19 reported from April 1, 2020 to May 2, 2023, comparing those with and without DS. Using multivariable logistic regression, we examined rates of hospitalization, intensive care unit (ICU) admission, respiratory support, and changes in cancer‐directed therapy. Results: Among 1408 CAYAs with hematologic malignancies, 55 had DS (CAYA‐DS). CAYA‐DS had higher rates of hospitalization, ICU admission, and respiratory support ( p < .001) than CAYAs without DS. Similarly, multivariable analyses found higher odds of hospitalization (odds ratio [OR] = 2.8, 95% confidence interval [CI]: 1.5–5.1), ICU admission (OR = 4.2, 95% CI: 1.9–9.1), and need for respiratory support (OR = 4.2, 95% CI: 2.0–8.8) among CAYA‐DS. Modifications to cancer‐directed therapy were more common among CAYA‐DS when related to neutropenia ( p = .001), but not when unrelated to neutropenia ( p = .88); CAYA‐DS did not have higher odds of changes to cancer‐directed therapy (OR = 1.20, 95% CI: 0.7–2.1). Conclusions: We identify CAYA‐DS with hematologic malignancies as a vulnerable subpopulation at greater risk for severe COVID‐19 infection. This can inform conversations with patients and families regarding therapeutic and preventive measures, as well as the risks and benefits of modifying chemotherapy in the setting of COVID‐19.
- 28 May 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (8) , e31082
Open AccessCOVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies
Introduction: Children, adolescents, and young adults (CAYAs) with Down syndrome (DS) and hematologic malignancies are particularly vulnerable to infections and related complications. There are limited data regarding COVID‐19 infections in this group. We aimed to understand the clinical course of COVID‐19 in this population. Methods: This observational study leverages the de‐identified clinical and sociodemographic data captured by the Pediatric Oncology COVID‐19 Case Report Registry (POCC) regarding CAYAs with cancer and COVID‐19. We evaluated CAYAs (≤21 years at COVID‐19 infection) with hematologic malignancies and COVID‐19 reported from April 1, 2020 to May 2, 2023, comparing those with and without DS. Using multivariable logistic regression, we examined rates of hospitalization, intensive care unit (ICU) admission, respiratory support, and changes in cancer‐directed therapy. Results: Among 1408 CAYAs with hematologic malignancies, 55 had DS (CAYA‐DS). CAYA‐DS had higher rates of hospitalization, ICU admission, and respiratory support ( p < .001) than CAYAs without DS. Similarly, multivariable analyses found higher odds of hospitalization (odds ratio [OR] = 2.8, 95% confidence interval [CI]: 1.5–5.1), ICU admission (OR = 4.2, 95% CI: 1.9–9.1), and need for respiratory support (OR = 4.2, 95% CI: 2.0–8.8) among CAYA‐DS. Modifications to cancer‐directed therapy were more common among CAYA‐DS when related to neutropenia ( p = .001), but not when unrelated to neutropenia ( p = .88); CAYA‐DS did not have higher odds of changes to cancer‐directed therapy (OR = 1.20, 95% CI: 0.7–2.1). Conclusions: We identify CAYA‐DS with hematologic malignancies as a vulnerable subpopulation at greater risk for severe COVID‐19 infection. This can inform conversations with patients and families regarding therapeutic and preventive measures, as well as the risks and benefits of modifying chemotherapy in the setting of COVID‐19.
- 16 April 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (8) , 1366-1373
Adolescents and young adults with cancer: the clinical course of COVID-19 infections
Adolescents and Young Adults (AYAs: 15-39 y) with cancer face unique vulnerabilities, yet remain under-represented on clinical trials, including adult registries of COVID-19 in cancer (AYAs: 8-12%). Thus, we leveraged the Pediatric Oncology COVID-19 Case Report (POCC) to examine the clinical course of COVID-19 among AYAs with cancer. POCC collects de-identified clinical and sociodemographic data regarding 0-39yo with cancer (AYAs = 37%) and COVID-19 from >100 institutions. Between 04/01/2020-11/28/2023, 191 older AYAs [22-39y] and 640 younger AYAs [15-21y] were captured. Older AYAs were less often hospitalized (p < .001), admitted to the intensive care unit (ICU, p = .02), and/or required respiratory support (p = .057). In multivariable analyses, older AYAs faced 80% lower odds of ICU admission but 2.3-times greater odds of changes to cancer-directed therapy. Unvaccinated patients had 5.4-times higher odds of ICU admission. Among AYAs with cancer, the COVID-19 course varies by age. These findings can inform pediatric/adult oncology teams surrounding COVID-19 management and prevention.
- 16 April 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (8) , 1366-1373
Adolescents and young adults with cancer: the clinical course of COVID-19 infections
Adolescents and Young Adults (AYAs: 15-39 y) with cancer face unique vulnerabilities, yet remain under-represented on clinical trials, including adult registries of COVID-19 in cancer (AYAs: 8-12%). Thus, we leveraged the Pediatric Oncology COVID-19 Case Report (POCC) to examine the clinical course of COVID-19 among AYAs with cancer. POCC collects de-identified clinical and sociodemographic data regarding 0-39yo with cancer (AYAs = 37%) and COVID-19 from >100 institutions. Between 04/01/2020-11/28/2023, 191 older AYAs [22-39y] and 640 younger AYAs [15-21y] were captured. Older AYAs were less often hospitalized (p < .001), admitted to the intensive care unit (ICU, p = .02), and/or required respiratory support (p = .057). In multivariable analyses, older AYAs faced 80% lower odds of ICU admission but 2.3-times greater odds of changes to cancer-directed therapy. Unvaccinated patients had 5.4-times higher odds of ICU admission. Among AYAs with cancer, the COVID-19 course varies by age. These findings can inform pediatric/adult oncology teams surrounding COVID-19 management and prevention.
- 1 April 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (4) , 491-502
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL
PURPOSE: Individuals diagnosed with cancer between 15 and 39 years (adolescent and young adult [AYA]) face unique vulnerability. Detail is lacking about care delivery for these patients, especially those with ALL. We address these knowledge gaps by describing AYA ALL care delivery details at National Cancer Institute Community Oncology Research Program (NCORP) (sub)affiliates by model of care. METHODS: Participating institutions treated at least one AYA with ALL from 2012 to 2016. Study-specific criteria were used to determine the number of unique clinical facilities (CFs) per NCORP and their model of care (adult/internal medicine [IM], pediatric, mixed [both]). Surveys completed by NCORPs for each CF by model of care captured size, resources, services, and communication. RESULTS: Among 84 participating CFs (adult/IM, n=47; pediatric, n=15; mixed, n=24), 34% treated 5-10 AYAs with ALL annually; adult/IM CFs more often treated <5 (adult/IM, 60%; pediatric, 40%; mixed, 29%). Referral decisions were commonly driven by an age/diagnosis combination (58%), with frequent ALL-specific age minimums (87%) or maximums (80%). Medical, navigational, and social work services were similar across models while psychology was available at more pediatric CFs (pediatric, 80%; adult/IM, 40%; mixed, 46%-54%). More pediatric or mixed CFs reported oncologists interacting with pediatric/adult counterparts via tumor boards (pediatric, 93%; adult/IM, 26%; mixed, 96%) or initiating contact (pediatric, 100%; adult/IM, 77%; mixed 96%); more pediatric CFs reported an affiliated counterpart (pediatric, 53%; adult, 19%). Most CFs reported no AYA-specific resources (79%) or meetings (83%-98%). CONCLUSION: System-level aspects of AYA ALL care delivery have not been examined previously. At NCORPs, these characteristics differ by models of care. Additional work is ongoing to investigate the impact of these facility-level factors on guideline-concordant care in this population. Together, these findings can inform a system-level intervention for diverse practice settings.
- 1 April 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (4) , 491-502
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL
PURPOSE: Individuals diagnosed with cancer between 15 and 39 years (adolescent and young adult [AYA]) face unique vulnerability. Detail is lacking about care delivery for these patients, especially those with ALL. We address these knowledge gaps by describing AYA ALL care delivery details at National Cancer Institute Community Oncology Research Program (NCORP) (sub)affiliates by model of care. METHODS: Participating institutions treated at least one AYA with ALL from 2012 to 2016. Study-specific criteria were used to determine the number of unique clinical facilities (CFs) per NCORP and their model of care (adult/internal medicine [IM], pediatric, mixed [both]). Surveys completed by NCORPs for each CF by model of care captured size, resources, services, and communication. RESULTS: Among 84 participating CFs (adult/IM, n=47; pediatric, n=15; mixed, n=24), 34% treated 5-10 AYAs with ALL annually; adult/IM CFs more often treated <5 (adult/IM, 60%; pediatric, 40%; mixed, 29%). Referral decisions were commonly driven by an age/diagnosis combination (58%), with frequent ALL-specific age minimums (87%) or maximums (80%). Medical, navigational, and social work services were similar across models while psychology was available at more pediatric CFs (pediatric, 80%; adult/IM, 40%; mixed, 46%-54%). More pediatric or mixed CFs reported oncologists interacting with pediatric/adult counterparts via tumor boards (pediatric, 93%; adult/IM, 26%; mixed, 96%) or initiating contact (pediatric, 100%; adult/IM, 77%; mixed 96%); more pediatric CFs reported an affiliated counterpart (pediatric, 53%; adult, 19%). Most CFs reported no AYA-specific resources (79%) or meetings (83%-98%). CONCLUSION: System-level aspects of AYA ALL care delivery have not been examined previously. At NCORPs, these characteristics differ by models of care. Additional work is ongoing to investigate the impact of these facility-level factors on guideline-concordant care in this population. Together, these findings can inform a system-level intervention for diverse practice settings.